The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing ...

BOTHELL, Wash., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs ...

The clinical development plan is a blueprint that brings a new drug discovery from preclinical development to market approval. It helps to regulate the process of drug discovery, ensuring patient ...